Bank of America’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $40.2M | Sell |
1,043,805
-148,125
| -12% | -$5.47M | ﹤0.01% | 1766 |
|
|
2025
Q4 | $42.3M | Sell |
1,191,930
-1,047,325
| -47% | -$29.4M | ﹤0.01% | 1673 |
|
|
2025
Q3 | $32.2M | Buy |
2,239,255
+838,290
| +60% | +$9.93M | ﹤0.01% | 2143 |
|
|
2025
Q2 | $10.1M | Buy |
1,400,965
+329,707
| +31% | +$1.83M | ﹤0.01% | 3220 |
|
|
2025
Q1 | $6.42M | Buy |
1,071,258
+1,032,191
| +2,642% | +$8.09M | ﹤0.01% | 3571 |
|
|
2024
Q4 | $305K | Sell |
39,067
-462,345
| -92% | -$4.61M | ﹤0.01% | 5872 |
|
|
2024
Q3 | $5.42M | Buy |
501,412
+95,095
| +23% | +$926K | ﹤0.01% | 3667 |
|
|
2024
Q2 | $3.43M | Sell |
406,317
-67,072
| -14% | -$509K | ﹤0.01% | 3974 |
|
|
2024
Q1 | $3.18M | Buy |
473,389
+401,742
| +561% | +$2.48M | ﹤0.01% | 4048 |
|
|
2023
Q4 | $421K | Sell |
71,647
-71,254
| -50% | -$546K | ﹤0.01% | 5613 |
|
|
2023
Q3 | $1.39M | Sell |
142,901
-3,257
| -2% | -$38.6K | ﹤0.01% | 4565 |
|
|
2023
Q2 | $1.73M | Sell |
146,158
-227,747
| -61% | -$2.61M | ﹤0.01% | 4338 |
|
|
2023
Q1 | $4.03M | Buy |
373,905
+112,499
| +43% | +$1.44M | ﹤0.01% | 3723 |
|
|
2022
Q4 | $3.02M | Buy |
261,406
+70,679
| +37% | +$876K | ﹤0.01% | 3886 |
|
|
2022
Q3 | $2.85M | Buy |
190,727
+144,807
| +315% | +$1.98M | ﹤0.01% | 3958 |
|
|
2022
Q2 | $414K | Buy |
45,920
+10,379
| +29% | +$70.8K | ﹤0.01% | 5567 |
|
|
2022
Q1 | $266K | Sell |
35,541
-3,139
| -8% | -$21.9K | ﹤0.01% | 6283 |
|
|
2021
Q4 | $332K | Sell |
38,680
-5,383
| -12% | -$46.8K | ﹤0.01% | 6174 |
|
|
2021
Q3 | $370K | Buy |
44,063
+26,523
| +151% | +$203K | ﹤0.01% | 5859 |
|
|
2021
Q2 | $142K | Sell |
17,540
-7,620
| -30% | -$64.4K | ﹤0.01% | 6302 |
|
|
2021
Q1 | $221K | Buy |
25,160
+11,972
| +91% | +$115K | ﹤0.01% | 5968 |
|
|
2020
Q4 | $148K | Buy |
13,188
+1,814
| +16% | +$19.9K | ﹤0.01% | 5780 |
|
|
2020
Q3 | $106K | Sell |
11,374
-3,506
| -24% | -$36.6K | ﹤0.01% | 5672 |
|
|
2020
Q2 | $27K | Sell |
14,880
-835
| -5% | -$1.55K | ﹤0.01% | 6181 |
|
|
2020
Q1 | $26K | Sell |
15,715
-7,734
| -33% | -$21.5K | ﹤0.01% | 6088 |
|
|
2019
Q4 | $68K | Sell |
23,449
-2,094
| -8% | -$8.55K | ﹤0.01% | 6152 |
|
|
2019
Q3 | $147K | Sell |
25,543
-5,128
| -17% | -$41.7K | ﹤0.01% | 5848 |
|
|
2019
Q2 | $322K | Sell |
30,671
-12,795
| -29% | -$170K | ﹤0.01% | 5358 |
|
|
2019
Q1 | $763K | Buy |
43,466
+18,580
| +75% | +$318K | ﹤0.01% | 4730 |
|
|
2018
Q4 | $438K | Buy |
24,886
+2,579
| +12% | +$76.3K | ﹤0.01% | 5027 |
|
|
2018
Q3 | $919K | Sell |
22,307
-3,568
| -14% | -$201K | ﹤0.01% | 4539 |
|
|
2018
Q2 | $1.49M | Buy |
+25,875
| New | +$1.24M | ﹤0.01% | 4206 |
|
Other funds holding COGT
DM
VPM
VCM
FFM
RI
TCM
Bank of America's COGT Position: Q1 2026 in Review
Bank of America reduced its Cogent Biosciences (COGT) stake by 12% in Q1 2026, selling an estimated $5.47M and leaving 1,043,805 shares worth $40.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1766.
Bank of America first reported a position in COGT in Q2 2018 and has held it in 32 quarters since. The position peaked at $42.3M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.
- Bank of America held 1,043,805 shares of Cogent Biosciences worth $40.2M as of Q1 2026.
- Bank of America sold 148,125 Cogent Biosciences shares in Q1 2026, an estimated $5.47M.
- Cogent Biosciences made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1766 holding.
- Bank of America first reported a position in Cogent Biosciences in Q2 2018 and has held it in 32 quarters since.
- Bank of America's Cogent Biosciences position peaked at $42.3M in Q4 2025.
- 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.